Virobay raises $300K to treat hepatitis C and autoimmune disorders
Virobay, developer of biological inhibitors to hepatitis C — which could also be used to treat autoimmune diseases, liver diseases, osteoporosis and some types of cancer — has brought in $300,000 in debt financing, according to a filing with the SEC. Based in Menlo Park, Calif., the company is backed by Alta Partners, Sutter Hill Ventures and TPG Growth.
Next Story: Detroit Auto Show: Our 5 green picks so far
Previous Story: Kicking off earnings season, Intel beats expectations
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
